Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Tumor × ulocuplumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1 Leukemia 1

Interventions

toripalimab 5 Injections 5 Nivolumab 4 pembrolizumab 3 tislelizumab 2 spartalizumab 2 Paclitaxel 2 Ipilimumab 2 zimberelimab 1 ulocuplumab 1 sotorasib 1 sintilimab 1 osimertinib 1 famitinib 1 donafenib 1 cemiplimab 1 binimetinib 1 avelumab 1 atezolizumab 1 WW Domain-Containing Oxidoreductase 1 SHR-1701 1 Immunotherapy, Adoptive 1 Gemcitabine 1 Cisplatin 1 Cetuximab 1 Carboplatin 1 Bevacizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02472977 2018-11-01

CXCessoR4

Bristol-Myers Squibb

Phase 1/2 Terminated

61 enrolled 11 charts

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡